Indian Pharma: Congress and FDA Continue Scrutiny of Foreign Drug Companies with Heightened Focus on Companies Located in India

12 February 2020
View Debevoise In Depth
Key takeaways:
  • India is a key supplier of drugs to the U.S. market and the future is bright for Indian pharmaceutical companies that can successfully comply with U.S. regulatory requirements.
  • Foreign pharmaceutical manufacturers, including those based in India, are subject to increasing Congressional and Food and Drug Administration (FDA) scrutiny due to a number of recent high-profile recalls of drugs manufactured abroad.
  • Congressional scrutiny is likely to continue due to the recent outbreak of the novel coronavirus originating in Wuhan City, China, which has the potential to disrupt pharmaceutical supply chains in China, India, and the United States.